Christopher Martell - Net Worth and Insider Trading

Christopher Martell Net Worth

The estimated net worth of Christopher Martell is at least $2 Million dollars as of 2024-05-09. Christopher Martell is the Director of Candel Therapeutics Inc and owns about 152,000 shares of Candel Therapeutics Inc (CADL) stock worth over $2 Million. Details can be seen in Christopher Martell's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Christopher Martell has not made any transactions after 2022-12-09 and currently still holds the listed stock(s).

Transaction Summary of Christopher Martell

To

Christopher Martell Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christopher Martell owns 1 companies in total, including Candel Therapeutics Inc (CADL) .

Click here to see the complete history of Christopher Martell’s form 4 insider trades.

Insider Ownership Summary of Christopher Martell

Ticker Comapny Transaction Date Type of Owner
CADL Candel Therapeutics Inc 2022-12-09 director

Christopher Martell Latest Holdings Summary

Christopher Martell currently owns a total of 1 stock. Christopher Martell owns 152,000 shares of Candel Therapeutics Inc (CADL) as of December 9, 2022, with a value of $2 Million.

Latest Holdings of Christopher Martell

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CADL Candel Therapeutics Inc 2022-12-09 152,000 9.97 1,515,440

Holding Weightings of Christopher Martell


Christopher Martell Form 4 Trading Tracker

According to the SEC Form 4 filings, Christopher Martell has made a total of 3 transactions in Candel Therapeutics Inc (CADL) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Candel Therapeutics Inc is the acquisition of 27,000 shares on December 9, 2022, which cost Christopher Martell around $51,030.

Insider Trading History of Christopher Martell

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christopher Martell Trading Performance

GuruFocus tracks the stock performance after each of Christopher Martell's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Christopher Martell is 7.1%. GuruFocus also compares Christopher Martell's trading performance to market benchmark return within the same time period. The performance of stocks bought by Christopher Martell within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Christopher Martell's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Christopher Martell

Average Return

Average return per transaction

Outperforming Transactions

0 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -0.31
Relative Return to S&P 500(%) -0.28

Christopher Martell Ownership Network

Ownership Network List of Christopher Martell

No Data

Ownership Network Relation of Christopher Martell


Christopher Martell Owned Company Details

What does Candel Therapeutics Inc do?

Who are the key executives at Candel Therapeutics Inc?

Christopher Martell is the director of Candel Therapeutics Inc. Other key executives at Candel Therapeutics Inc include Chief Financial Officer Jason Amello , See Remarks Seshu Tyagarajan , and director & President & CEO Paul Peter Tak .

Candel Therapeutics Inc (CADL) Insider Trades Summary

Over the past 18 months, Christopher Martell made 2 insider transaction in Candel Therapeutics Inc (CADL) with a net purchase of 54,000. Other recent insider transactions involving Candel Therapeutics Inc (CADL) include a net purchase of 38,032 shares made by Joseph C Papa , a net purchase of 15,985 shares made by Paul Peter Tak , and a net purchase of 13,358 shares made by Seshu Tyagarajan .

In summary, during the past 3 months, insiders sold 0 shares of Candel Therapeutics Inc (CADL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Candel Therapeutics Inc (CADL) were sold and 128,181 shares were bought by its insiders, resulting in a net purchase of 128,181 shares.

Candel Therapeutics Inc (CADL)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Candel Therapeutics Inc Insider Transactions

No Available Data

Christopher Martell Mailing Address

Above is the net worth, insider trading, and ownership report for Christopher Martell. You might contact Christopher Martell via mailing address: Candel Therapeutics, Inc., 117 Kendrick St Suite 450, Needham Ma 02494.

Discussions on Christopher Martell

No discussions yet.